Motilal Oswal Financial Services has issued a Buy recommendation for Aurobindo Pharma Ltd.

Prabhudas Lilladher has reiterated a BUY call on Aurobindo Pharma with a revised target price of Rs 1,440, underpinned by robust growth in U.S.

KRChoksey Research has maintained its "BUY" recommendation for Aurobindo Pharma with a target price of Rs. 1,591, offering an upside potential of 33.5%.

Aurobindo Pharma shares opened at Rs 1,225 and touched a high of Rs 1,247.30, reflecting its robust market presence.

Geojit Financial Services has reaffirmed a BUY rating on Aurobindo Pharma Limited with a target price of Rs 1,540, implying a potential upside of 25% from the current market price of Rs 1,229.

Indian markets closed negative due to selling in banking and blue-chip stocks. Adani Group stocks pulled the indices down.